Last updated: 17 July 2019 at 8:26pm EST

Richard L Harrison Net Worth




The estimated Net Worth of Richard L Harrison is at least $2.44 Milione dollars as of 12 January 2017. Richard Harrison owns over 20,634 units of Glaukos stock worth over $966,476 and over the last 9 years Richard sold GKOS stock worth over $1,475,400.

Richard Harrison GKOS stock SEC Form 4 insiders trading

Richard has made over 8 trades of the Glaukos stock since 2015, according to the Form 4 filled with the SEC. Most recently Richard exercised 20,634 units of GKOS stock worth $150,216 on 12 January 2017.

The largest trade Richard's ever made was selling 30,000 units of Glaukos stock on 3 May 2016 worth over $737,700. On average, Richard trades about 11,151 units every 34 days since 2015. As of 12 January 2017 Richard still owns at least 7,701 units of Glaukos stock.

You can see the complete history of Richard Harrison stock trades at the bottom of the page.



What's Richard Harrison's mailing address?

Richard's mailing address filed with the SEC is C/O GLAUKOS CORPORATION, 20651 MERIT CIRCLE, SUITE 103, LAGUNA HILLS, CA, 92653.

Insiders trading at Glaukos

Over the last 11 years, insiders at Glaukos have traded over $300,254,118 worth of Glaukos stock and bought 17,376 units worth $317,262 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Gilbert H Kliman e Jonathan Silverstein. On average, Glaukos executives and independent directors trade stock every 25 days with the average trade being worth of $8,240,079. The most recent stock trade was executed by Gilbert H Kliman on 9 September 2024, trading 3,000 units of GKOS stock currently worth $96,000.



What does Glaukos do?

glaukos corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures to transform the treatment of glaucoma, one of the world’s leading causes of blindness. glaukos has pioneered micro-invasive glaucoma surgery, or migs, to revolutionize the traditional glaucoma treatment and management paradigm. the company launched the istent trabecular micro-bypass stent, its first migs device, in the united states in 2012. glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression. glaukos believes the istent is the smallest medical device ever approved by the food and drug administration, or fda, measuring 1.0 mm long and 0.33 mm wide. in june 2015, the company completed an initial public offering and its shares are now traded on the new york stock exchange unde



What does Glaukos's logo look like?

Glaukos Corporation logo

Complete history of Richard Harrison stock trades at Glaukos

Data
#
Ditta
Persona
Trans.
Transazione
Azioni Prezzo per azione Prezzo totale Azioni dopo Fonte
12 Jan 2017 Richard L Harrison
Tesoriere, CFO e Segretario
Opzione 20,634 $7.28 $150,216
12 Jan 2017
7,701
6 Jan 2017 Richard L Harrison
Tesoriere, CFO e Segretario
Opzione 20,634 $4.63 $95,535
6 Jan 2017
22,022
27 Jul 2016 Richard L Harrison
Tesoriere, CFO e Segretario
Opzione 10,000 $3.98 $39,800
27 Jul 2016
11,388
12 Jul 2016 Richard L Harrison
Tesoriere, CFO e Segretario
Opzione 5,700 $3.98 $22,686
12 Jul 2016
7,088
20 Jun 2016 Richard L Harrison
Tesoriere, CFO e Segretario
Opzione 4,300 $3.98 $17,114
20 Jun 2016
5,688
3 May 2016 Richard L Harrison
Tesoriere, CFO e Segretario
Vendita 30,000 $24.59 $737,700
3 May 2016
1,388
3 May 2016 Richard L Harrison
Tesoriere, CFO e Segretario
Vendita 30,000 $24.59 $737,700
3 May 2016
1,388
31 Dec 2015 Richard L Harrison
Tesoriere, CFO e Segretario
Acquistare 1,388 $15.30 $21,236
31 Dec 2015
4,656


Glaukos executives and stock owners

Glaukos executives and other stock owners filed with the SEC include: